首页> Breast cancer research and treatment> BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors.

BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors.

导出 OA

翻译打印收藏纠错

第一作者： Kavitha,Däster

第一单位： Breast Center Zurich, Zurich, Switzerland. Kavitha.daester@brust-zentrum.ch.;University of Basel, Basel, Switzerland. Kavitha.daester@brust-zentrum.ch.

作者： Kavitha,Däster ^[1] ; Jürgen,Hench ^[2] ; Maren,Diepenbruck ^[3] ; Katrin,Volkmann ^[3] ; Adelin,Rouchon ^[3] ; Marta,Palafox ^[3] ; Jorge Gomez,Miragaya ^[3] ; Bogdan Tiberius,Preca ^[3] ; Christian,Kurzeder ^[4] ; Walter Paul,Weber ^[4] ; Mohamed,Bentires-Alj ^[3] ; Savas Deniz,Soysal ^[5] ; Simone,Muenst ^[6]

作者单位： Breast Center Zurich, Zurich, Switzerland. Kavitha.daester@brust-zentrum.ch.;University of Basel, Basel, Switzerland. Kavitha.daester@brust-zentrum.ch. ^[1] Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. ^[2] Tumor Heterogeneity Metastasis and Resistance, Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland. ^[3] University of Basel, Basel, Switzerland.;Breast Center, University Hospital Basel, Basel, Switzerland. ^[4] University of Basel, Basel, Switzerland.;Praxis Chirurgie Im Zentrum, Basel, Switzerland. ^[5] University of Basel, Basel, Switzerland.;Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland. ^[6]

关键词 BRCA promoter methylation Metastatic breast cancer PARP inhibitors Triple-negative breast cancer